Aurobindo Pharma is currently trading at Rs. 963.55, up by 12.90 points or 1.36% from its previous closing of Rs. 950.65 on the BSE.
The scrip opened at Rs. 965.00 and has touched a high and low of Rs. 966.50 and Rs. 942.00 respectively. So far 68651 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 968.85 on 09-Nov-2023 and a 52 week low of Rs. 397.30 on 03-Feb-2023.
Last one week high and low of the scrip stood at Rs. 968.85 and Rs. 857.00 respectively. The current market cap of the company is Rs. 56613.39 crore.
The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 40.74% and 7.42% respectively.
Aurobindo Pharma has received approval for purchase of entire equity shares of Theranym Biologics, a step-down wholly owned subsidiary of the Company, from Curateq Biologics, also a wholly owned subsidiary of the company, and make Theranym Biologics a direct subsidiary of the company. The Board of Directors of the Company at its meeting held November 9, 2023, has approved the same.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1817.70 |
Dr. Reddys Lab | 1337.85 |
Cipla | 1477.75 |
Lupin | 2166.15 |
Zydus Lifesciences | 974.60 |
View more.. |